Health and Pharmaceuticals

Dental care chain sets price range for IPO

Pacific Smiles float to raise close to $50m at top end of price range.

Broker firms get $1.5bn of Medibank allocation

Share submissions by brokers on behalf of clients almost $12bn. Forces government to scale back entitlements.

Leighton wins Healthscope contract

Leighton subsidiary Thiess will design and construct new $1bn Sydney hospital.

Estia set for $1.2bn float

Morgan Stanley analysts deliver $1.2bn valuation for aged-care provider ahead of IPO.

Healthscope wins $1bn hospital tender

by AAP
Recently floated private health care provider to build 488-bed hospital on Sydney's northern beaches.

nib on track for higher earnings

by AAP
Private health insurer eyes long-term boost from growing healthcare spending.

Egging on female employees

Facebook, Apple and others are offering female staff the chance to freeze their eggs to help them forge ahead with their careers. Is it the ultimate staff benefit, or something scary?

Pfizer posts rise in Q3 profit

Drugmaker narrows full-year outlook as results top expectations.

Novartis posts 45% lift in Q3 profit

by AFP
Swiss drugmaker hails 'very strong quarter' as solid sales boost result.

The truth behind the Medibank hype

Reports that demand for Medibank shares is 'several times' the number on offer have fooled many, but previous floats explain why all is not as it seems.

Orion Health sets indicative price for IPO

Hospital software provider sets price range for IPO between $NZ4.30 and $NZ5.70.

Estia roadshow kicks off

Aged-care business remains on track for pre-Christmas listing on ASX.

Doors open on Medibank Private sale

by AAP
Retail investors can start applying to buy shares in Medibank Private float.

Alchemia shares plunge 83% on drug failure

by AAP
Biotech company 'extremely disappointed' with results of cancer drug trial.

CSL grabs a second lucky prize

Few companies get to buy assets that put them on a global footing, at depressed prices. CSL has now done it twice.

CSL to buy Novartis business

CSL set to acquire Novartis’ global influenza vaccine business for $US275m, will combine with bioCSL.

Estia eyes pre-Christmas IPO

PE firm Quadrant redrafting plans to list aged care business to capitalise on strong IPO market.

Quadrant fast-tracks Estia float

Private equity firm now plans to list aged care business before Christmas.

P&G posts 34% fall in Q3 profit

Group to exit Duracell battery business after heavy writedown.

Colgate-Palmolive earnings fall in Q3

Group downgrades full-year earnings forecast as foreign exchange rates weigh.